CARGOCONNECT-NOVEMBER 2020 - Flipbook - Page 18
for driving process
mong the problems for pharmaceutical supply chains
during this pandemic are the restrictions and impact
of COVID-19 on China and India, two of the largest
global producers of active pharmaceutical ingredients (APIs) and generics.
Since the outbreak started in China and lockdowns were imposed, supply from their manufacturing facilities has reduced. The true extent is still
difficult to quantify although the typical workforce is now entirely engaged
in their business operations.
18 | CargoConnect November 2020
Providing adequate supplies of pharmaceuticals
has taken on accelerated
precedence in order to
satisfy demand, not just
domestically but also
internationally to countries without the facilities to manufacture certain drugs in sufficient
quantities. As other sectors adjust to operating in the ‘new normal’,
pharmaceutical companies will be no different
in examining ways that
and the industr y as a
whole can help to transform its supply chains
for a new era.